

## Drug Monograph

Drug/Drug **Latuda (lurasidone) tablet / Atypical Antipsychotic**

Class:

Prepared for: MO HealthNet

Prepared by: Xerox Heritage, LLC

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

<b>Purpose:</b>	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
<b>Dosage Forms:</b>	Each 60 mg tablet of Latuda contains 60 mg of Lurasidone	
<b>Manufacturer:</b>	Sunovion Pharmaceuticals Inc. Marlborough, MA 01752	
<b>Indications:</b>	Latuda is an atypical antipsychotic that is indicated for the treatment of schizophrenia and Depressive Episodes Associated with Bipolar I Disorder as monotherapy and as adjunctive therapy with lithium or valproate.	
<b>Costs:</b>	\$20.25 per tablet of Latuda. Wholesale Acquisition Cost	
<b>Summary of Findings:</b>	MO HealthNet Division recommends this product be added to the existing Atypical Antipsychotics and Polypharmacy Clinical Edits and the 15 Day First Fill Fiscal Edit.	
<b>Status Recommendation:</b>	<input type="checkbox"/> Prior Authorization (PA) Required	<input type="checkbox"/> Open Access
	<input checked="" type="checkbox"/> Clinical Edits and Fiscal Edit	<input type="checkbox"/> PDL
<b>Type of PA Criteria:</b>	<input type="checkbox"/> Increased Risk of ADE	<input type="checkbox"/> Preferred Agent
	<input checked="" type="checkbox"/> Appropriate Indications	<input type="checkbox"/> No PA Required

Prepared By: Malena Jost, Pharm.D. Candidate  
Date: October 14, 2013